Bluejay Diagnostics Files 8-K on Shareholder Votes

Ticker: BJDX · Form: 8-K · Filed: 2025-06-20T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing

TL;DR

Bluejay Diagnostics filed an 8-K on shareholder votes, check for updates on corporate actions.

AI Summary

Bluejay Diagnostics, Inc. filed an 8-K on June 20, 2025, reporting on matters submitted to a vote of security holders as of June 18, 2025. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). The principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

Why It Matters

This filing indicates that Bluejay Diagnostics held a vote of its security holders, which could pertain to significant corporate actions or governance changes.

Risk Assessment

Risk Level: low — This is a routine filing reporting on a vote of security holders, not indicating immediate financial distress or significant operational changes.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Bluejay Diagnostics' security holders on or before June 18, 2025?

The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals voted upon in the provided text.

What is the significance of the filing date being June 20, 2025, while the earliest event reported is June 18, 2025?

This indicates that the corporate action or vote occurred on June 18, 2025, and the company is reporting it to the SEC within the required timeframe, with the filing officially made on June 20, 2025.

Where are Bluejay Diagnostics' principal executive offices located?

The principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

In which state is Bluejay Diagnostics, Inc. incorporated?

Bluejay Diagnostics, Inc. is incorporated in Delaware.

What is the company's SEC file number?

The company's SEC file number is 001-41031.

From the Filing

0001213900-25-055724.txt : 20250620 0001213900-25-055724.hdr.sgml : 20250620 20250618185437 ACCESSION NUMBER: 0001213900-25-055724 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250618 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250620 DATE AS OF CHANGE: 20250618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bluejay Diagnostics, Inc. CENTRAL INDEX KEY: 0001704287 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 473552922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41031 FILM NUMBER: 251058206 BUSINESS ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: (978) 631-0152 MAIL ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 8-K 1 ea0246255-8k_bluejay.htm CURRENT REPORT false 0001704287 0001704287 2025-06-18 2025-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 18, 2025   Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter)   delaware   001-41031   47-3552922 (State or Other Jurisdiction of Incorporation or Organization)   (Commission File No.)   (I.R.S. Employer Identification No.)   360 Massachusetts Avenue , Suite 203 Acton , MA 01720 (Address of principal executive offices and zip code)   ( 844 ) 327-7078 (Registrant’s telephone number, including area code)     (Former name or former address, if changed from last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol (s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   BJDX   The Nasdaq Capital Market             Item 5.07 Submission of Matters to a Vote of Security Holders.   On June 18, 2025, Bluejay Diagnostics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). As of May 15, 2025, the record date for the Annual Meeting, there were 1,494,182 shares of the Company’s common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 616,134 were present in person or represented by proxy, which constituted a quorum

View on Read The Filing